Alan

1348 for the win.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC The SAC contains NWBO’s allegations. The ruling says those allegations were sufficient to proceed.

Neither document says: “Damages are a few pennies per share.” That’s your conclusion, not the Court’s

Have a blessed evening. Your nor I knows the outcome, those are the facts!

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC The ruling supports the surviving claims being tied to ~40.5M shares.
What it doesn’t support is your next leap: “therefore damages are a few pennies per share.” That’s your damages estimate, not the Court’s finding.
You’re being disingenuous by spreading a false narrative.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC Fair enough, but it doesn’t limit it. Discovery will be the determining factor. You can’t put a dollar amount on it or limit it. Doing so is disingenuous and not factual. We wait and see.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC Thank you, the ruling limits the surviving loss-causation theories to those transactions.

What it doesn’t do is determine damages. The Court decided what claims survive, not their ultimate value.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC Then cite the ruling.

Not your interpretation of the ruling. The actual language where the Court says recovery is capped at 40M shares.

I’ve seen your conclusion repeatedly. I haven’t seen the citation.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC Notice you’ve gone from citing the ruling to citing your own confidence.

“The Judge ruled X” is an argument.

“I understand spoofing, therefore X” is just your opinion

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC The Judge found the SAC adequately alleged damages. He didn’t determine final damages or adopt your 40M-share formula.

Discovery is ongoing. New evidence can support, challenge, or refine damages analyses by either side’s experts.

Surviving an MTD isn’t a damages award.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC The SAC is NWBO’s allegation, not the Court’s damages finding.
If quoting a complaint automatically established damages, there’d be no need for discovery, experts, summary judgment, or trial. The Court allowed claims to proceed. Can’t assign a $ amount. We wait and see.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC The Court didn’t calculate damages. It narrowed claims at the MTD stage.

Your “40M shares × 2-6%” formula isn’t a court finding—it’s your personal damages theory. Discovery isn’t complete, experts haven’t testified, and liability hasn’t been determined. All baseless assumptions.

[Alan @alanb5347]

@Tiggersdad2 @rjmsoflo The court narrowed claims; it didn’t determine liability, damages, or the full factual record. That’s what discovery and trial are for.

[Alan @alanb5347]

@Tiggersdad2 @FlyEaglesFly529 @TradeCNBC The court narrowed claims; it didn’t determine liability, damages, or the full factual record. That’s what discovery and trial are for.

[Alan @alanb5347]

@andrewcaravello This assumes they are cooperating with NWBO we have no confirmation. We don’t know what the agreement was.

[Thomas Owen McCaffrey @ThomasOwenMcCa1]

On Monday of last week I had my 9 month maintenance M.R.I @UCLA
Once again, all clear, no sign of tumor recurrence. This didn’t shock ⚡️ me one bit. If it shocked you, you don’t believe in science 🧪 or you have a vested interest in denying it. How much longer are we going to let innocent people die just to make roughly 20 to 25 people ridiculously wealthy. Or put them through ☠️ poisonous treatments…

@kendricklamar @kshaughnessy2 @LisainNJUSA @ElvirPons @NYMag @metacollectiveG
@peter_brit

[Alan @alanb5347]

@BIO99_BIO99 I asked AI to validate this, here is the response:

NWBO’s Roswell deal licenses dendritic-cell (DC) technology only (Kalinski platform). It does not include SurVaxM survivin peptide-vaccine trials or CAR-T programs. Those studies aren’t DCVax and aren’t NWBO catalysts.

[Hoffmann @hoffmann6383]

Spoofing Case Update - $NWBO v. Citadel, et al

Case No.: 1:22-cv-10185
Docket: https://t.co/2vLwDOXAki

Today we saw a letter filing by $NWBO asking for all the case management deadlines to be extended by 120 days. $NWBO's counsel blames the substitution of counsel, Les Goldman's passing, delay tactics by Defendants, among other things.

I've attached an image of $NWBO's proposed deadlines. The Defendants do not consent to the extension of deadlines.

Some interesting points in today's letter:

➡️Current Document Production

"NWBio has so far produced 3,056 documents. Defendants have produced far less. Defendant G1 Execution Services LLC has only produced 10 documents, Defendant Virtu Americas LLC produced 26 documents, and Defendant Citadel Securities LLC produced 132 documents. The other Defendants—Canaccord Genuity LLC, GTS Securities LLC, Instinet LLC, and Lime Trading Corp.—have produced no documents at all."

➡️Nonparty Subpoenas

"There have also been delays in receiving productions from nonparties. For example, in June 2025, NWBio served subpoenas to Depository Trust & Clearing Corporation (“DTCC”) and Financial Industry Regulatory Authority, Inc. (“FINRA”)—both of which are critical sources of relevant information concerning the trades at issue. Following NWBio’s persistent inquiries, DTCC only recently produced documents and FINRA is still gathering documents for future production, with partial production anticipated by mid-January and an uncertain timeline to complete production of archived data. Based on information gleaned from DTCC’s production, NWBio served additional follow-up requests to Defendants, for which responses are due today. Moreover, in October 2025, NWBio served a subpoena to nonparty OTC Link LLC, the scope of production for which is still being negotiated. All of the foregoing documents are critical to NWBio’s prosecution of this case."

[Alan @alanb5347]

@hoffmann6383 @ThomasViking1 This is what I found by trying to find a transcript but I can’t find more information on if the trials are ongoing or moving into next phase

DCVax-L – Early GBM / phase I/II
DCVax-L – Ovarian Cancer
DCVax-Direct – Solid Tumors

[Alan @alanb5347]

@hoffmann6383 @ThomasViking1 No during the asm she made mention to other trails that were done and went good and ongoing ones. Idk know all the different names but I assume NWBO is involved if she mentions them?

[Alan @alanb5347]

@hoffmann6383 @ThomasViking1 I was half working half listening, I just remembered her referencing a few other trials beside what we are waiting for approval on.

I’m just wondering if there is more going on now.

[Alan @alanb5347]

@hoffmann6383 @ThomasViking1 Do you know anything about the other trials she mentioned I haven’t seen anything on it

[Alan @alanb5347]

@Mike_MacConnell @ThePatriotOasis @shaunking @JohnsHopkins I couldn’t find the company statement from 2017